<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34977926</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1569-9285</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>34</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>02</Day>
            </PubDate>
          </JournalIssue>
          <Title>Interactive cardiovascular and thoracic surgery</Title>
          <ISOAbbreviation>Interact Cardiovasc Thorac Surg</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Are NOACs as safe and efficient as VKA regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?</ArticleTitle>
        <Pagination>
          <StartPage>739</StartPage>
          <EndPage>743</EndPage>
          <MedlinePgn>739-743</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivab363</ELocationID>
        <Abstract>
          <AbstractText>A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was: 'Are NOACs as safe and efficient as vitamin K antagonist regarding thromboembolic prophylaxis and major bleeding in patients with surgical bioprosthesis and atrial fibrillation within 3 months of surgery?' Altogether more than 324 papers were found using the reported search, of which 6 represented the best evidence to answer the clinical question. The authors, journal, date and country of publication, patient group studied, study type, relevant outcomes and results of these papers are tabulated. The RIVER and ENAVLE trials showed non-inferiority of rivaroxaban (regarding mean time free from composite of death, major cardiovascular events or major bleeding at 12 months) and edoxaban (composite of death, clinical thromboembolic events or asymptomatic intracardiac thrombosis; and major bleeding) when compared with vitamin K antagonist. These studies include a low number of patients within 3 months of index surgery and overall low statistical power regarding this particular subgroup of patients. Data derived from lower evidence studies are compatible with the aforementioned findings. The available evidence suggests that non-vitamin K antagonist anticoagulants are as safe and as efficient as vitamin K antagonist regarding thromboembolic prophylaxis and bleeding event rates in patients with surgical bioprosthesis and atrial fibrillation within 3 months of bioprosthesis implantation. However, this evidence is derived from a limited number of studies with important methodological limitations. Expanding non-vitamin K antagonist anticoagulant recommendation to the early postoperative period warrants more confirmatory research.</AbstractText>
          <CopyrightInformation>© The Author(s) 2022. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Magro</LastName>
            <ForeName>Pedro Lamares</ForeName>
            <Initials>PL</Initials>
            <Identifier Source="ORCID">0000-0002-5521-9232</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Cardio-thoracic Surgery, Hospital de Santa Cruz, Carnaxide, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sousa-Uva</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Cardio-thoracic Surgery, Hospital de Santa Cruz, Carnaxide, Portugal.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Interact Cardiovasc Thorac Surg</MedlineTA>
        <NlmUniqueID>101158399</NlmUniqueID>
        <ISSNLinking>1569-9285</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005343">Fibrinolytic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12001-79-5</RegistryNumber>
          <NameOfSubstance UI="D014812">Vitamin K</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001705" MajorTopicYN="Y">Bioprosthesis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005343" MajorTopicYN="N">Fibrinolytic Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006470" MajorTopicYN="N">Hemorrhage</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013923" MajorTopicYN="Y">Thromboembolism</DescriptorName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014812" MajorTopicYN="N">Vitamin K</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Anticoagulation</Keyword>
        <Keyword MajorTopicYN="Y">Bioprosthesis</Keyword>
        <Keyword MajorTopicYN="Y">DOAC</Keyword>
        <Keyword MajorTopicYN="Y">Non-vitamin K antagonist anticoagulant</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>3</Day>
          <Hour>5</Hour>
          <Minute>58</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34977926</ArticleId>
        <ArticleId IdType="pmc">PMC9070514</ArticleId>
        <ArticleId IdType="doi">10.1093/icvts/ivab363</ArticleId>
        <ArticleId IdType="pii">6491900</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Dunning J, Prendergast B, Mackway JK.. 
Towards evidence-based medicine in cardiothoracic surgery: best BETS. Interact CardioVasc Thorac Surg 2003;2:405–9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17670084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guimarães PO, Pokorney SD, Lopes RD, Wojdyla DM, Gersh BJ, Giczewska A. 
et al.
Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: insights from the ARISTOTLE trial. Clin Cardiol 2019.  ;42:568–71.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6522998</ArticleId>
            <ArticleId IdType="pubmed">30907005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Carnicelli AP, De Caterina R, Halperin JL, Renda G, Ruff CT, Trevisan M. 
et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban for the prevention of thromboembolism in patients with atrial fibrillation and bioprosthetic valves. Circulation 2017;135:1273–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28209729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Guimarães HP, Lopes RD, de Barros E Silva PGM, Liporace IL, Sampaio RO, Tarasoutchi F, Hoffmann-Filho CR. 
et al. RIVER Trial Investigators. Rivaroxaban in patients with atrial fibrillation and a bioprosthetic mitral valve. N Engl J Med 2020;383:2117–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33196155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Shim CY, Seo J, Kim YJ, Lee SHD, Caterina R, Lee S, Hong GR; Explore the Efficacy and Safety of Edoxaban in Patients after Heart Valve Repair or Bioprosthetic Valve Replacement (ENAVLE) study group. Efficacy and safety of edoxaban in patients early after surgical bioprosthetic valve implantation or valve repair: a randomized clinical trial. J Thorac Cardiovasc Surg 2021;S0022-5223(21)00228-2.</Citation>
        </Reference>
        <Reference>
          <Citation>
Pasciolla S, Zizza LF, Le T, Wright K.. 
Comparison of the efficacy and safety of direct oral anticoagulants and warfarin after bioprosthetic valve replacements. Clin Drug Investig 2020;40:839–45.</Citation>
        </Reference>
        <Reference>
          <Citation>
Nauffal V, Trinquart L, Osho A, Sundt TM, Lubitz SA, Ellinor PT.. 
Non-vitamin K antagonist oral anticoagulant vs warfarin for post cardiac surgery atrial fibrillation. Ann Thorac Surg 2021;112:1392–1401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33440173</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
